Friday, July 10, 2026

Drug profile · INN

dicloxacillin sodium

dicloxacillin sodium (PATHOCIL) is a penicillin-binding protein inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — dicloxacillin sodium
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.89

Quick answer

dicloxacillin sodium (PATHOCIL) is a penicillin-binding protein inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN dicloxacillin sodium
Brand PATHOCIL
Mechanism Penicillin-binding protein inhibitor
Target Penicillin-binding protein
Route ORAL
Formulation CAPSULE

Mechanism of action

Penicillin-binding protein inhibitor

Primary target: Penicillin-binding protein

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. amoxicillin Bacterial penicillin-binding protein inhibitor
  2. ampicillin sodium Bacterial penicillin-binding protein inhibitor
  3. ampicillin/ampicillin trihydrate Bacterial penicillin-binding protein inhibitor
  4. cefaclor Bacterial penicillin-binding protein inhibitor
  5. cefadroxil/cefadroxil hemihydrate Bacterial penicillin-binding protein inhibitor
  6. cefazolin sodium Bacterial penicillin-binding protein inhibitor

Frequently asked questions

What is dicloxacillin sodium?

dicloxacillin sodium (PATHOCIL) is a penicillin-binding protein inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for dicloxacillin sodium?

PATHOCIL is a marketed brand name for dicloxacillin sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of dicloxacillin sodium?

dicloxacillin sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.